By admin | Published:
November 6, 2007
George Sopko
REFERENCE: Abstract 3771, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
GEORGE SOPKO, National Heart, Lung And Blood Institute, Bethesda, Maryland
COMMENT: JENNIFER MIERES, New York University
A new study presented to the American Heart Association meeting found women taking hormone replacement therapy since the menopause had a protective cardiovascular benefit. This was greater the earlier HRT was initiated and the women who took HRT had lower rates of coronary artery disease. Chief study author George Sopko spoke with Sarah Maxwell at the Orlando meeting.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Cardiovascular | Tagged arteries, artery, blood, cardiovascular, coronary, disease, george sopko, heart, hormone, jennifer mieres, lung, therapies, therapy |
By admin | Published:
November 6, 2007
Ernst Rietzschel
Jennifer Mieres
REFERENCE: News Briefing, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
ERNST RIETZSCHEL, University of Ghent, Belgium
COMMENT: JENNIFER MIERES, New York University
Women who used the contraceptive pill had increases in atherosclerotic plaque in their carotid and femoral arteries of between 20 and 30 percent by the time they reached late middle age. This is the finding of the ASKLEPIOS study conducted by the University of Ghent in which plaque was measured by ultrasound in 2 500 healthy men and women. Ernst Rietzschel presented data from the study to the 2007 Sessions of the AHA, and afterwards discussed the findings with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 6, 2007
Gregg Stone
REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone presented data from the TAXUS DES trials which looked at patients surviving more than a year after receiving either paclitaxel-eluting or bare metal stents. After his talk at the American Heart Association he discussed his findings with Sarah Maxwell.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 6, 2007
Philip Barter
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
PHILIP BARTER, Heart Research Institute, Sydney, Australia
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore
A randomized double-blind study involving over 15,000 patients at high cardiovascular risk which looked at the new agent torcetrapib (an inhibitor of cholesteryl ester transfer protein, CETP) resulted in higher mortality in the experimental arm. The study compared torcetrapib plus atorvastatin with atorvatstin alone. Inhibition of CETP increases HDL levels and reduces LDL levels and should combat atherosclerosis. Sarah Maxwell spoke with Philip Barter who presented data on the ILLUMINATE trial at the American Heart Association meeting in Orlando.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 6, 2007
Uwe Zeymer
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients receiving primary angioplasty for acute myocardial infarction. So according to Uwe Zeymer who presented findings on this it can be used in this setting just as it is already being used in elective PCI. Sarah Maxwell interviewed Dr Zeymer at the Orlando conference.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 5, 2007
Anthony Fung
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
ANTHONY FUNG, University of British Columbia, Vancouver
Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as effective as longer infusions for patients receiving non-emergency percutaneous intervention. So said Anthony Fung at the first session of Late breaking Clinical Trials held at the American Heart Association’s annual meeting in Orlando. He talked with Peter Goodwin about his findings.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 5, 2007
Laura Mauri
Raymond Gibbons
REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
LAURA MAURI, Brigham and Woman’s Hospital, Boston Massachusetts
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester, Minnesota
The largest study to date looking at long-term outcomes of bare metal stents as compared with drug eluting stents in patients who have undergone PCI was presented to the American Heart Association annual meeting. There was no increased mortality for patients who received drug eluting stents in a Massachussets based population. Sarah Maxwell spoke with investigator to Laura Mauri at the Orlando meeting.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Cardiovascular | Tagged cardiovascular, comments, drug, drugs, heart, investigation, journal, patient, podcast, podcasting, presented, stent, stenting, stents, study |
Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results
Ake Hjalmarson
Gordon Tomaselli
N Engl J Med 2007;357
AKE HJALMARSON, Sahlgrenska University, Göteborg
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore
The lipid lowering agent rosuvastatin did not bring a significant benefit to older patients with systolic heart failure, according to the findings of the CORONA study released at the American Heart Association sessions in Orlando. Ake Hjalmarson talked with Peter Goodwin about the implications this has for using statins in older patients with heart failure.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.